Latest News

Stay up to date with the latest stock market news from around the world. From breaking news written by our finance analysts to event-driven market news on a global scale.

NYSE:ONTO
NYSE:ONTOSemiconductor

Onto Innovation (ONTO) Is Up 13.9% After Record AI Packaging Demand And Major HBM Agreement - Has The Bull Case Changed?

Onto Innovation recently reported that strong demand for its metrology and inspection tools in AI and advanced semiconductor packaging, supported by a record backlog and a major volume agreement with a leading HBM maker, is driving expectations for more than 30% revenue growth in advanced packaging in 2026. This momentum not only reinforces Onto Innovation’s role in critical AI and high‑bandwidth memory production, but also highlights how higher-margin advanced packaging tools and improving...
NYSE:PCOR
NYSE:PCORSoftware

A Look At Procore Technologies (PCOR) Valuation After Its New CFO And CRO Appointments

Procore Technologies (PCOR) has reshuffled its top leadership, naming Rachel Pyles as Chief Financial Officer and Walt Hearn as Chief Revenue Officer, while reaffirming its 2026 guidance and continued focus on AI driven platform expansion. See our latest analysis for Procore Technologies. The leadership reshuffle comes as the share price trades at US$58.02, with a 7 day share price return of 4.05% and a 90 day share price return showing a 22.14% decline, while the 3 year total shareholder...
NasdaqGS:ALKS
NasdaqGS:ALKSBiotechs

Is Alkermes (ALKS) Building a Durable Sleep-Disorder Franchise With Its Brilliance Phase 3 Bet?

In early April 2026, Alkermes plc announced it had begun the Brilliance phase 3 program, a set of randomized, double-blind, placebo-controlled studies testing its oral orexin 2 receptor agonist alixorexton in adults with narcolepsy type 1 and type 2, following earlier phase 1 and phase 2 work and Breakthrough Therapy designation in narcolepsy type 1. The launch of these Brilliance Studies signals Alkermes’ intention to build a differentiated sleep-disorder franchise around orexin agonism,...
NasdaqGS:FFIN
NasdaqGS:FFINBanks

How Investors May Respond To First Financial Bankshares (FFIN) Record Profit Amid Fraud Loss And New CEO

Recently, First Financial Bankshares’ board of directors promoted David Bailey to CEO and reported a record quarterly net income with strong deposit growth, while absorbing a US$21.55 million credit loss tied to fraudulent activity by a commercial borrower. This combination of leadership transition and resilient financial performance offers insight into how the bank is managing risk while pursuing its growth plans. We’ll explore how Bailey’s appointment and the record quarterly results shape...
NYSE:MKL
NYSE:MKLInsurance

A Look At Markel Group (MKL) Valuation After Recent Share Price Weakness

Recent share performance and business mix Markel Group (MKL) has recently drawn attention after a one-month return of about a 4% decline and a past three-month return of roughly an 11% decline, contrasting with a positive one-year total return of 13.1%. The company operates across insurance and a range of industrial and consumer businesses. Markel Insurance generates about US$10.3b of revenue, alongside contributions from the Industrial, Consumer and Other, Financial, and Corporate...
NYSE:AVNT
NYSE:AVNTChemicals

A Look At Avient’s (AVNT) Valuation After Keybanc Downgrade Shifts Rating To Sector Weight

Keybanc analyst Aleksey Yefremov recently shifted his rating on Avient (AVNT) from Overweight to Sector Weight, a change that puts fresh attention on how the stock compares with its peers. See our latest analysis for Avient. Avient shares recently pulled back, with a 1 day share price return of a 3.65% decline and a 30 day share price return of a 4.15% decline. However, the 1 year total shareholder return of 21.30% and the year to date share price return of 10.60% suggest momentum has...
SEHK:1093
SEHK:1093Pharmaceuticals

CSPC Pharmaceutical Group (SEHK:1093) Valuation Check After Aprepitant Injection Approval

CSPC Pharmaceutical Group (SEHK:1093) has drawn fresh attention after securing regulatory approval in China for its Aprepitant Injection, a next generation NK 1 antagonist aimed at preventing postoperative nausea and vomiting in adults. See our latest analysis for CSPC Pharmaceutical Group. Investors appear to be responding to a mix of product approvals, the 2025 earnings release and ongoing capital returns. A 1 year total shareholder return of 80.59% and a 90 day share price return of 9.22%...
NYSE:LNN
NYSE:LNNMachinery

A Look At Lindsay (LNN) Valuation After Earnings Miss And Softer Growth Outlook

Lindsay (LNN) is back in focus after reporting quarterly results that missed analyst expectations, with softer demand in both Irrigation and Infrastructure, weaker operating margins, and management flagging limited near term growth catalysts. See our latest analysis for Lindsay. The weak quarter has been followed by a sharp reset in expectations, with a 1 month share price return showing a decline of 20.51% and a 1 year total shareholder return showing a loss of 12.90%, pointing to fading...
NYSE:ENS
NYSE:ENSElectrical

Assessing EnerSys (ENS) Valuation After Earnings Beat And Battery Plant Realignment

EnerSys (ENS) has drawn attention after announcing the closure of its legacy lead-acid battery plant in Tijuana, with production shifting to its Thin Plate Pure Lead facility in Springfield, Missouri. See our latest analysis for EnerSys. The stock’s recent 14.32% 1 month share price return and 17.66% year to date share price return suggest momentum has been building, while the 120.67% 1 year total shareholder return points to stronger gains over a longer stretch. If you are looking beyond...
NasdaqCM:MARA
NasdaqCM:MARASoftware

A Look At MARA Holdings (MARA) Valuation After Major Bitcoin Sale And AI Infrastructure Shift

MARA Holdings (MARA) is shaking up its business model after selling 15,133 Bitcoin for about US$1.1b, cutting its workforce by 15%, and retiring roughly 30% of its convertible debt. See our latest analysis for MARA Holdings. The latest restructuring news has arrived alongside a 1 day share price return of 8.33% and a 7 day share price return of 11.74%. However, the 1 year total shareholder return of 22.65% and 5 year total shareholder return of 82.60% indicate that longer term momentum has...
NYSE:ESTC
NYSE:ESTCSoftware

FedRAMP High Win And New Security Automation Tools Could Be A Game Changer For Elastic (ESTC)

In March 2026, Elastic announced that Elastic Cloud Hosted on AWS GovCloud (US) achieved FedRAMP High authorization, enabling U.S. federal agencies to run sensitive, high-impact workloads for security, Zero Trust, and AI-powered mission applications on a standardized, rigorously vetted cloud platform. Elastic also introduced Elastic Workflows as a native automation layer inside Elastic Security, aiming to replace standalone SOAR tools by combining scripted playbooks with AI agents that act...
HLSE:LUMO
HLSE:LUMOReal Estate

Lumo Kodit Oyj (HLSE:LUMO) Valuation After Occupancy-Led Revenue And Guidance Update

Occupancy-led update draws attention to Lumo Kodit Oyj Lumo Kodit Oyj (HLSE:LUMO) is back in focus after reporting higher occupancy that supported revenue and net rental income, and reaffirmed full year revenue growth and funds from operations guidance. See our latest analysis for Lumo Kodit Oyj. The share price has reacted quickly to the occupancy update, with a 1-day share price return of 1.22% and 7-day share price return of 4.16%. However, the 1-year total shareholder return of a 4.25%...
NYSE:BRSL
NYSE:BRSLHospitality

New Multicurrency Credit Lines Could Be A Game Changer For Brightstar Lottery (BRSL)

In March 2026, Brightstar Lottery PLC entered into new senior secured multicurrency revolving credit facilities totaling US$650 million and €1,000 million, aligning covenants across its major debt agreements and refinancing older facilities to support general corporate purposes. By locking in a five-year funding backstop with terms linked to its public credit ratings, Brightstar Lottery has materially expanded its financial flexibility and tightened the link between its borrowing costs and...
NasdaqGS:VLY
NasdaqGS:VLYBanks

A Look At Valley National Bancorp (VLY) Valuation As JPMorgan Trims Target But Keeps Overweight Rating

Valley National Bancorp (VLY) is back in focus after JPMorgan reiterated its Overweight rating while trimming its price target, as investors weigh the bank’s 25 million share buyback and broader capital plans. See our latest analysis for Valley National Bancorp. That reassessment has cooled very short term enthusiasm, with a 1 day share price return of a 0.16% decline, but the 7 day share price return of 4.37% and 1 year total shareholder return of 59.59% suggest momentum has been building...
NasdaqGM:RLAY
NasdaqGM:RLAYBiotechs

Is Relay Therapeutics (RLAY) Building a Durable Precision-Medicine Platform with Its Zovegalisib Strategy?

Relay Therapeutics recently announced that initial clinical and preclinical data for its PI3Kα inhibitor zovegalisib in vascular anomalies will be presented at the International Society for the Study of Vascular Anomalies World Congress 2026 in May, based on results that supported advancing the regimen into the ongoing Phase 3 ReDiscover-2 trial. By aiming a mutant-selective PI3Kα inhibitor at both PIK3CA-driven vascular anomalies and certain breast cancers, Relay Therapeutics is linking a...
ISE:GVR
ISE:GVRConsumer Durables

April 2026's Undervalued Small Caps With Insider Action In Global

In the midst of geopolitical tensions and energy market volatility, global markets have shown resilience, with smaller-cap indexes posting solid gains amid a backdrop of mixed economic indicators. As investors navigate these uncertain times, the focus on small-cap stocks with insider action can be particularly intriguing due to their potential for growth and unique positioning in the market.
TSE:4980
TSE:4980Electronic

High Growth Tech Stocks To Watch In April 2026

As global markets navigate the complexities of Middle East tensions and energy market volatility, major U.S. stock indexes have shown resilience, with the Nasdaq Composite leading gains amidst a backdrop of mixed labor data and tentative geopolitical de-escalation. In this environment, identifying high growth tech stocks involves looking for companies that demonstrate robust adaptability to shifting economic conditions and possess innovative capabilities that can thrive even amid broader...
TSE:4568
TSE:4568Pharmaceuticals

3 Global Stocks Valued At Up To 36.1% Less Than Intrinsic Estimates

Global markets have been navigating a landscape marked by geopolitical tensions and energy market volatility, with major indices like the Nasdaq Composite and S&P 500 showing resilience amid these challenges. As investors seek opportunities in this fluctuating environment, identifying undervalued stocks—those trading below their intrinsic value estimates—can be an appealing strategy, offering potential for long-term growth when market conditions stabilize.
SWX:VACN
SWX:VACNMachinery

Global Growth Stocks With Significant Insider Ownership

As global markets navigate the complexities of Middle East tensions and energy market volatility, major indices like the Nasdaq Composite have shown resilience with notable gains, reflecting a cautiously optimistic sentiment amid geopolitical uncertainties. In such an environment, growth companies with significant insider ownership often attract attention due to their potential for alignment between management and shareholder interests, which can be particularly appealing when navigating...
SET:SIRI
SET:SIRIReal Estate

CNMC Goldmine Holdings And 2 Other Global Penny Stocks To Watch

Global markets have recently experienced volatility due to geopolitical tensions in the Middle East and fluctuations in energy prices, yet major indices like the Nasdaq Composite and S&P 500 have managed to post gains. Amidst these market dynamics, penny stocks continue to capture investor interest as they represent smaller or newer companies that can offer unique growth opportunities at lower price points. By focusing on those with strong balance sheets and sound fundamentals, investors may...
TSE:6834
TSE:6834Electronic

Undiscovered Gems in Global Markets to Explore This April 2026

In the midst of geopolitical tensions and energy market volatility, global markets have shown resilience with major U.S. indices posting gains amid hopes of de-escalating conflicts in the Middle East. As smaller-cap indexes also see solid performance, investors might find opportunities in lesser-known stocks that could benefit from improving economic indicators like consumer confidence and manufacturing activity. Amid these conditions, identifying promising stocks often involves looking for...
TSE:3106
TSE:3106Luxury

3 Global Dividend Stocks Offering Up To 3.5% Yield

As global markets navigate through geopolitical tensions and fluctuating energy prices, investors are keenly observing how these factors impact economic indicators like inflation and employment. Amidst this backdrop, dividend stocks can offer a measure of stability, providing income even when market conditions are volatile. A good dividend stock in the current environment is one that not only offers a reliable yield but also demonstrates resilience against economic uncertainties.
NYSE:JNJ
NYSE:JNJPharmaceuticals

ICOTYDE Psoriasis Data And JNJ-4804 Funding Could Be A Game Changer For Johnson & Johnson (JNJ)

In late March 2026, Johnson & Johnson reported 52-week Phase 3 data showing its oral peptide ICOTYDE maintained high complete skin clearance rates and a consistent safety profile in adults and adolescents with moderate-to-severe plaque psoriasis, while Royalty Pharma announced a US$500 million R&D co-funding agreement to advance JNJ-4804 for autoimmune diseases. These developments highlight Johnson & Johnson’s push to build a differentiated immunology portfolio, pairing late-stage oral...